Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.
Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, Kastritis E, Papatheodorou A, Terpos E. Voskaridou E, et al. Among authors: christoulas d. Haematologica. 2009 May;94(5):725-8. doi: 10.3324/haema-tol.2008.000893. Haematologica. 2009. PMID: 19407319 Free PMC article.
High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E. Voskaridou E, et al. Among authors: christoulas d. Horm Metab Res. 2012 Nov;44(12):909-13. doi: 10.1055/s-0032-1312618. Epub 2012 May 11. Horm Metab Res. 2012. PMID: 22581647 Clinical Trial.
Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.
Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E. Voskaridou E, et al. Among authors: christoulas d. Haematologica. 2008 Oct;93(10):1588-90. doi: 10.3324/haematol.12849. Epub 2008 Aug 12. Haematologica. 2008. PMID: 18698086 Free article. Clinical Trial. No abstract available.
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E, Anargyrou K, Tsionos K, Dimopoulos MA, Zervas K; Greek Myeloma Study Group. Terpos E, et al. Among authors: christoulas d. Haematologica. 2009 Mar;94(3):372-9. doi: 10.3324/haematol.2008.000638. Haematologica. 2009. PMID: 19252175 Free PMC article. Clinical Trial.
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.
Voskaridou E, Ntanasis-Stathopoulos I, Papaefstathiou A, Christoulas D, Dimopoulou M, Repa K, Papatheodorou A, Peppa M, Terpos E. Voskaridou E, et al. Among authors: christoulas d. Blood Adv. 2018 Nov 13;2(21):2837-2847. doi: 10.1182/bloodadvances.2018023085. Blood Adv. 2018. PMID: 30381400 Free PMC article. Clinical Trial.
Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis.
Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Sonnleitner L, Papaefstathiou A, Dimopoulou M, Missbichler A, Kanellias N, Repa K, Papatheodorou A, Peppa M, Hawa G, Terpos E. Voskaridou E, et al. Among authors: christoulas d. Hematology. 2019 Dec;24(1):318-324. doi: 10.1080/16078454.2019.1570617. Hematology. 2019. PMID: 30665323 Free article. Clinical Trial.
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A. Dimopoulos MA, et al. Among authors: christoulas d. Ann Oncol. 2009 Jan;20(1):117-20. doi: 10.1093/annonc/mdn554. Epub 2008 Aug 9. Ann Oncol. 2009. PMID: 18689864 Free article.
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, Dimopoulos MA. Terpos E, et al. Among authors: christoulas d. Ann Oncol. 2012 Oct;23(10):2681-2686. doi: 10.1093/annonc/mds068. Epub 2012 Apr 6. Ann Oncol. 2012. PMID: 22492699 Free article.
71 results